View email in your browser

Caladrius Biosciences to Host 2015 Fourth Quarter
and Full Year Financial Results Conference Call

March 15 at 5:00 pm EST

BASKING RIDGE, N.J. (March 8, 2016) – Caladrius Biosciences, Inc. (NASDAQ: CLBS) (“Caladrius”), a cell therapy company combining an industry-leading development and manufacturing services provider with a therapeutic development pipeline, announces today that the Company will release financial results for the fourth quarter and full year of 2015 after the U.S. financial markets close on Tuesday, March 15, 2016.Caladrius’ management will host a conference call for the investment community beginning at 5:00 pm ET on Tuesday, March 15, 2016, to discuss the financial results and to answer questions.Shareholders and other interested parties may participate in the conference call by dialing (877) 562-4460 (US) or (513) 438-4106 (International) and entering passcode 95709216. The call will also be broadcast live on the Internet via the Company’s website at The call will be archived on the Company’s website for 90 days at

About Caladrius Biosciences
Caladrius Biosciences, Inc., through its wholly-owned subsidiary, PCT, is a leading development and manufacturing partner to the cell therapy industry.  Caladrius works with its clients to overcome the fundamental challenges of cell therapy manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support.  Around this core expertise, Caladrius strategically develops select product candidates, which currently includes an innovative therapy for type 1 diabetes based on a proprietary platform technology for immunomodulation. For more information, visit

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding our expected revenues and capital expenditures, personnel reductions, as well as the potential of CLBS03 in the treatment of recent-onset type 1 diabetes and the expected cost savings associated with the termination of the CLBS20 study. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 2, 2015, and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.

Past Press Releases
February 17, 2015
Caladrius Biosciences licenses dermatology cell technology to AiVita Biomedical
January 11, 2016
Caladrius Biosciences Out-licenses CD34 Technology to SPS Cardio, LLC for Chronic Heart Failure and Acute Myocardial Infarction
January 6, 2016
Caladrius Tightens Strategic Focus and Provides 2016 Revenue Guidance

February 10, 2016
Source Capital's 2016 Disruptive Growth & Healthcare Conference
February 9, 2016
18th Annual BIO CEO & Investor Conference
January 28, 2016
Novel Cardiovascular Therapeutics Summit
Contact Us
Anne Marie Fields
Senior Vice President
Phone: +1-212-838-3777

Caladrius Biosciences, Inc.
Eric Powers
Communications and Marketing
Phone: +1-212-584-4173


Rainer Poertner - Chief Analyst    

Please visit our sites and We would appreciate if you could
pass our newsletter on to your friends and colleagues. We always appreciate your feedback and comments.

If you are interested in a research report for your public company, please contact us at

StockWatchIndex  and SWI Research (SWI) are not registered investment advisers and the information  provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. SWI may have been compensated for the  publication of the information herein and may hold positions in any of the stocks mentioned, which could be considered a conflict of interest. The included information is subject to change without notice. Please visit!legal-ease/lmvw1  for a full text of our Disclaimer, Privacy policy and Terms of Use.
Copyright © 2016 DynamicMarketConcepts, All rights reserved.

unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp